​

Tarsus Pharmaceuticals (TARS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

TARS Stock Forecast

Tarsus Pharmaceuticals (TARS) stock forecast, based on 9 Wall Street analysts, predicts a 12-month average price target of $64.00, with a high of $72.00 and a low of $58.00. This represents a 29.95% increase from the last price of $49.25.

$20 $31 $42 $53 $64 $75 High: $72 Avg: $64 Low: $58 Last Closed Price: $49.25

TARS Stock Rating

Tarsus Pharmaceuticals stock's rating consensus is Buy, based on 9 Wall Street analysts. The breakdown includes 1 Strong Buy (11.11%), 7 Buy (77.78%), 1 Hold (11.11%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 9 0 1 7 1 Strong Sell Sell Hold Buy Strong Buy

TARS Price Target Upside V Benchmarks

TypeNameUpside
StockTarsus Pharmaceuticals29.95%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts-35
Avg Price Target-$64.00$63.20
Last Closing Price$49.25$49.25$49.25
Upside/Downside-29.95%28.32%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25161--8
Mar, 25261--9
Feb, 25261--9
Jan, 25261--9
Dec, 24261--9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 06, 2025Jefferies$58.00$43.5733.12%17.77%
Jan 27, 2025Balaji PrasadBarclays$62.00$48.7827.10%25.89%
Jan 22, 2025Francois BriseboisOppenheimer$72.00$47.1452.74%46.19%
Sep 23, 2024Francois BriseboisOppenheimer$63.00$34.5882.19%27.92%
May 13, 2024Oren LivnatH.C. Wainwright$61.00$37.0064.86%23.86%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 06, 2025JefferiesBuyBuyhold
Jan 27, 2025BarclaysOverweightOverweighthold
Jan 22, 2025OppenheimerOutperformOutperformhold
Nov 29, 2024GuggenheimBuyBuyhold
Oct 22, 2024OppenheimerOutperformOutperformhold
Oct 11, 2024GuggenheimBuyBuyhold
Sep 23, 2024OppenheimerOutperformOutperformhold
May 13, 2024H.C. WainwrightBuyBuyhold
May 10, 2024BarclaysOverweightOverweighthold
May 09, 2024OppenheimerOutperformOutperformhold

Financial Forecast

EPS Forecast

$-10 $-6 $-2 $2 $6 $10 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.67$-2.52$-4.62$-3.07----
Avg Forecast$-0.57$-2.36$-4.79$-3.22$-1.69$1.91$4.78$7.06
High Forecast$-0.48$-2.08$-4.46$-2.94$-0.31$3.02$5.57$7.76
Low Forecast$-0.66$-2.60$-5.22$-3.47$-2.64$0.50$3.99$6.37
Surprise %17.54%6.78%-3.55%-4.66%----

Revenue Forecast

$0 $180M $360M $540M $720M $900M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$57.03M$25.82M$17.45M$182.95M----
Avg Forecast$49.07M$25.86M$9.70M$175.34M$317.67M$513.16M$708.62M$832.14M
High Forecast$54.62M$27.87M$12.17M$181.03M$335.41M$518.42M$763.13M$896.15M
Low Forecast$43.25M$23.48M$7.15M$171.31M$295.08M$507.89M$655.85M$770.17M
Surprise %16.22%-0.16%79.83%4.34%----

Net Income Forecast

$-200M $-110M $-20M $70M $160M $250M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-13.83M$-62.09M$-135.89M$-115.55M----
Avg Forecast$-16.83M$-69.44M$-135.89M$-94.26M$-63.17M$51.65M$140.45M$207.30M
High Forecast$-14.24M$-61.14M$-130.95M$-86.50M$-9.09M$88.73M$163.63M$228.03M
Low Forecast$-19.30M$-76.46M$-153.50M$-102.01M$-77.64M$14.57M$117.28M$187.23M
Surprise %-17.82%-10.59%-22.60%----

TARS Forecast FAQ

Is Tarsus Pharmaceuticals stock a buy?

Tarsus Pharmaceuticals stock has a consensus rating of Buy, based on 9 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 7 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Tarsus Pharmaceuticals is a favorable investment for most analysts.

What is Tarsus Pharmaceuticals's price target?

Tarsus Pharmaceuticals's price target, set by 9 Wall Street analysts, averages $64 over the next 12 months. The price target range spans from $58 at the low end to $72 at the high end, suggesting a potential 29.95% change from the previous closing price of $49.25.

How does Tarsus Pharmaceuticals stock forecast compare to its benchmarks?

Tarsus Pharmaceuticals's stock forecast shows a 29.95% upside, underperforming the average forecast for the healthcare stocks sector (35.25%) and underperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Tarsus Pharmaceuticals over the past three months?

  • April 2025: 12.50% Strong Buy, 75.00% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 22.22% Strong Buy, 66.67% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 22.22% Strong Buy, 66.67% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.

What is Tarsus Pharmaceuticals’s EPS forecast?

Tarsus Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.69, marking a -44.95% decrease from the reported $-3.07 in 2024. Estimates for the following years are $1.91 in 2026, $4.78 in 2027, and $7.06 in 2028.

What is Tarsus Pharmaceuticals’s revenue forecast?

Tarsus Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $317.67M, reflecting a 73.64% increase from the reported $182.95M in 2024. The forecast for 2026 is $513.16M, followed by $708.62M for 2027, and $832.14M for 2028.

What is Tarsus Pharmaceuticals’s net income forecast?

Tarsus Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-63.166M, representing a -45.34% decrease from the reported $-116M in 2024. Projections indicate $51.65M in 2026, $140.45M in 2027, and $207.3M in 2028.